Systematic prioritization of druggable mutations in ~5000 genomes across 16 cancer types using a structural genomics-based approachS

Medicine & Life Sciences

• Genomics 100%
• Genome 67%
• Mutation 55%
• Neoplasms 31%
• Proteins 21%
• Atlases 21%
• Ligands 20%
• Missense Mutation 20%
• Protein Binding 19%
• Binding Sites 15%
• Drug Repositioning 13%
• Oncogene Proteins 11%
• Precision Medicine 10%
• Pharmaceutical Preparations 8%
• X-Rays 7%
• Technology 6%
• Therapeutics 1%

Chemical Compounds

• Mutation 83%
• Protein 18%
• Binding Site 12%
• Drug Target 10%
• Drug 9%
• X-Ray 5%
• Amount 3%